Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Flunitrazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 9/20 | 0.80 |
| ▸ | GABRA5 known ✓ | P31644 | 9/20 | 0.80 |
| ▸ | GABRA3 known ✓ | P34903 | 9/20 | 0.80 |
| ▸ | GABRG2 known ✓ | P18507 | 8/20 | 0.80 |
| ▸ | GABRB3 known ✓ | P28472 | 8/20 | 0.80 |
| ▸ | GABRA2 known ✓ | P47869 | 8/20 | 0.80 |
| ▸ | GABRB2 known ✓ | P47870 | 7/20 | 0.80 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.68 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.68 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.68 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.68 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.68 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.68 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.68 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.68 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.80 |
| ▸ | GHSR | Q92847 | 2/20 | 0.80 |
| ▸ | CCKBR | P32239 | 2/20 | 0.80 |
| ▸ | MC3R | P41968 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flunitrazepam SCHEMBL15936037 | 0.91 | GABRA1 (0.66) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Flunitrazepam SCHEMBL19183070 | 0.91 | GABRA1 (0.66) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Flunitrazepam SCHEMBL29902314 | 0.90 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Flunitrazepam SCHEMBL29372584 | 0.90 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Flunitrazepam SCHEMBL8812488 | 0.90 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Flunitrazepam SCHEMBL16922172 | 0.90 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Flunitrazepam SCHEMBL44169 | 0.90 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Flunitrazepam SCHEMBL8364961 | 0.89 | GABRA1 (0.64) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Nimetazepam SCHEMBL29374297 | 0.87 | LMNA (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Nimetazepam SCHEMBL79886 | 0.87 | LMNA (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175513-A1 | ALL NATURAL, NON-TOXIC SUBLINGUAL DRUG DELIVERY SYSTEMS | SENTAR PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
| EP-2814460-B1 | GLUCOSE-RESPONSIVE MICROGELS FOR CLOSED LOOP INSULIN DELIVERY | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180078600-A1 | Healthy Tan Type of Antioxidant Defense | LUND ERIC (US) | 2018-03-22 | — | — | US | disclosed |
| US-20170266118-A1 | ALL NATURAL, NON-TOXIC SUBLINGUAL DRUG DELIVERY SYSTEMS | SENTAR PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20160331693-A1 | ALL NATURAL, NON-TOXIC SUBLINGUAL DRUG DELIEVERY SYSTEMS | SCILABS PHARMACEUTICALS (US) | 2016-11-17 | — | — | US | disclosed |
| US-9339529-B2 | Glucose-responsive microgels for closed loop insulin delivery | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-05-17 | — | — | US | disclosed |
| WO-2015119641-A1 | ALL NATURAL, NON-TOXIC SUBLINGUAL DRUG DELIVERY SYSTEMS | SCILABS PHARMACEUTICALS (US) | 2015-08-13 | — | — | WO | disclosed |
| US-20150030641-A1 | GLUCOSE-RESPONSIVE MICROGELS FOR CLOSED LOOP INSULIN DELIVERY | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2015-01-29 | — | — | US | disclosed |
| EP-2814460-A2 | GLUCOSE-RESPONSIVE MICROGELS FOR CLOSED LOOP INSULIN DELIVERY | Massachusetts Institute Of Technology (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013123492-A2 | GLUCOSE-RESPONSIVE MICROGELS FOR CLOSED LOOP INSULIN DELIVERY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2319500-A1 | Rapid acting drug delivery compositions | Biodel, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2106790-A1 | Rapid acting drug delivery compositions | Biodel, Inc. (US) | 2009-10-07 | — | — | EP | disclosed |
| US-20070235365-A1 | Rapid Acting Drug Delivery Compositions | BIODEL INC. | 2007-10-11 | — | — | US | disclosed |
| US-7279457-B2 | Rapid acting drug delivery compositions | BIODEL, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| WO-2007098058-A2 | DEVICE FOR SUBLINGUAL DRUG DELIVERY USING IONTOPHORESIS | BIODEL, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070191757-A1 | Method and Device for Sublingual Drug Delivery Using Iontophoresis | BIODEL INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1740154-A1 | RAPID ACTING DRUG DELIVERY COMPOSITIONS | Biodel, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050214251-A1 | Rapid acting drug delivery compositions | BIODEL, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005089722-A1 | RAPID ACTING DRUG DELIVERY COMPOSITIONS | BIODEL, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030641-A1 | GLUCOSE-RESPONSIVE MICROGELS FOR CLOSED LOOP INSULIN DELIVERY | IAPP, GPR119, LIPE | GABRA1 3154/4885GABRA5 3013/4885GABRA3 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.